Patrick P. Gleason, PharmD, Director of Clinical Outcomes Assessment, Prime Therapeutics, discusses the rates at which patients will not follow a prescribed therapeutic plan due to cost-sharing. Specifically, patients starting multiple sclerosis, rheumatoid arthritis, and oral oncology medication regimens with more than a $100 cost-share will be less likely to start the drug therapy.
Patrick P. Gleason, PharmD, Director of Clinical Outcomes Assessment, Prime Therapeutics, discusses the rates at which patients will not follow a prescribed therapeutic plan due to cost-sharing. Specifically, patients starting multiple sclerosis, rheumatoid arthritis, and oral oncology medication regimens with more than a $100 cost-share will be less likely to start the drug therapy.
ACA Network Regulatory Filings Are Inaccurate, Poorly Match Provider Directories
September 16th 2025A secret shopper survey (N = 8306) in Pennsylvania’s Affordable Care Act (ACA) Marketplace found inconsistencies between carrier regulatory filings and provider directories, frequent inaccuracies in regulatory filings, and challenges in securing timely appointments.
Read More
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More